Eli Lilly and Company Reports Third-Quarter 2012 Results

Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.